Skip to main content

Meeting the Needs of Patients With Moderate to Severe Ulcerative Colitis: Novel Targets Mean New Opportunities - May 21, 2021 [CME/CE SYMPOSIUM 243]


CME/CE Virtual Symposium

SAVE THE DATE!
Friday, May 21, 2021
4:15 PM PDT | 5:15 PM MDT| 6:15 PM CDT| 7:15 PM EDT

Please take the pretest prior to accessing the symposium.

Please contact info@mededicus.com with any questions. Thank you!


FACULTY

William J. Sandborn, MD (Chair)
Distinguished Professor of Medicine
Division of Gastroenterology
University of California, San Diego
La Jolla, California

Marla C. Dubinsky, MD
Professor of Pediatrics and Medicine
Chief, Pediatric Gastroenterology and Nutrition
Mount Sinai Kravis Children’s Hospital
Co-Director, Susan and Leonard Feinstein Inflammatory Bowel Disease Clinical Center
Icahn School of Medicine at Mount Sinai
New York, New York

David T. Rubin, MD
Joseph B. Kirsner Professor of Medicine
Chief, Section of Gastroenterology, Hepatology, and Nutrition
University of Chicago Medicine
Chicago, Illinois

CONTINUING MEDICAL EDUCATION INFORMATION

Activity Description and Purpose

Ulcerative colitis remains challenging to control and substantially degrades patient-related quality of life. Limitations with current treatments create the need for new treatment breakthroughs that are effective and well tolerated. This CME/CE symposium will review the latest data on several of these emerging treatments and new treatment guidelines and strategies to better recognize the effect of ulcerative colitis on patient quality of life.

Target Audience

This educational activity is intended for gastroenterologists, gastroenterology physician assistants, and nurse practitioners involved in the care of patients with ulcerative colitis.

Learning Objectives
After completing this activity, participants will be better able to:
  • Discuss the importance of considering the effect of ulcerative colitis on patients’ quality of life
  • Integrate disease activity and quality of life assessments into routine management of ulcerative colitis
  • Describe the limitations associated with current treatments for moderate to severe ulcerative colitis
  • Review current guidelines for treatment escalation as part of the management of moderate to severe ulcerative colitis
  • Summarize recent clinical trials on emerging S1P treatments in ulcerative colitis
  • Identify patients who would be good candidates for treatment with S1P modulators if and when they are approved

For Physicians:

ACCME Accreditation Statement

MedEdicus is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AMA PRA Credit Designation Statement
MedEdicus designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For Nurses:

Interprofessional Joint Accreditation Statement

In support of improving patient care, Amedco is jointly accredited by the ACCME, the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nursing Credit
Amedco LLC designates this activity for a maximum of 1.5 ANCC contact hours.

Disclosure Policy
MedEdicus requires that anyone who is in a position to control the content of this educational activity disclose all relevant financial relationships with any commercial interest. Financial relationship information is collected and resolved prior to the educational activity.

Faculty
Marla C. Dubinsky, MD, is a consultant for AbbVie Inc, Arena Pharmaceuticals, Inc, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Genentech, Inc, Gilead, Janssen Global Services, LLC, Pfizer Inc, Prometheus Biosciences, Takeda Pharmaceuticals USA, Inc, and UCB SA; is a contracted researcher for AbbVie Inc, Janssen Global Services, LLC, Pfizer Inc, and Prometheus Biosciences; has ownership interest in Trellus Health Inc; and receives other funding (licensing fee) from Takeda Pharmaceuticals USA, Inc.

David T. Rubin, MD, is a consultant for AbbVie Inc, AbGenomics, Allergan, Arena Pharmaceuticals, Inc, Atlantica, Bellatrix Pharmaceuticals, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, CDx Diagnostics, Celgene Corporation, Check-Cap, Dizal Pharmaceutical, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Galen Limited, Genentech, Inc, Gilead, Ichnos Sciences, InDex Pharmaceuticals Holding AB, Iterative Scopes, Inc, Janssen Global Services, LLC, Materia Prima, Pfizer Inc, Prometheus Laboratories, Reistone Biopharma, Takeda Pharmaceuticals USA, Inc, and Techlab, Inc; and receives grant support from Takeda Pharmaceuticals USA, Inc.

William J. Sandborn, MD, is a consultant for AbbVie Inc, Abivax, Admirx Inc, Alfasigma SpA, Alimentiv, Alivio Therapeutics, Allakos Inc, Amgen Inc, Applied Molecular Transport Inc, Arena Pharmaceuticals, Inc, Bausch & Lomb Incorporated, BeiGene, Bellatrix Pharmaceuticals, Boehringer Ingelheim International GmbH, Boston Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, Celltrion, Celularity Inc, Cosmo Pharmaceuticals NV, Eli Lilly and Company, Escalier Biosciences BV, Equillium, Inc, F. Hoffmann-La Roche Ltd, Forbion, Genentech, Inc, Gilead, Glenmark Pharmaceuticals, Gossamer Bio, Immunic, Inc, InDex Pharmaceuticals Holding AB, Intact Therapeutics, Inc, Janssen Global Services, LLC, Kyverna Therapeutics, Inc, Landos Biopharma, Inc, Oppilan Pharma, Otsuka America Pharmaceutical, Inc, Pandion Therapeutics, Pfizer Inc, Progenity, Inc, Prometheus Biosciences, Protagonists Therapeutics, Inc, Provention Bio, Inc, Reistone Biopharma, Salix Pharmaceuticals, Inc, Seres Therapeutics, Shanghai Pharma Biotherapeutics USA, Inc, Shire, Shoreline Biosciences, Sublimity Therapeutics, Surrozen, Takeda Pharmaceuticals USA, Inc, Theravance Biopharma, Inc, Thetis Pharmaceuticals LLC, Tillotts Pharma AG, UCB SA, Vedanta Biosciences, Inc, Ventyx Biosciences, Inc, Vimalan Biosciences, Inc, Vivelix Pharmaceuticals, Vivreon Biosciences, and Zealand Pharma A/S; is a contracted researcher for AbbVie Inc, Abivax, Arena Pharmaceuticals, Inc, Boehringer Ingelheim International GmbH, Celgene Corporation, Eli Lilly and Company, Genentech, Inc, Gilead, GlaxoSmithKline, Janssen Global Services, LLC, Pfizer Inc, Prometheus Biosciences, Seres Therapeutics, Shire, Takeda Pharmaceuticals USA, Inc, and Theravance Biopharma, Inc; and has ownership interest (stocks) in Allakos Inc, BeiGene, Gossamer Bio, Oppilan Pharma, Prometheus Biosciences, Progenity, Inc, Shoreline Biosciences, Ventyx Biosciences, Inc, Vimalan Biosciences, Inc, and Vivreon Biosciences.

Peer Reviewer
This activity was peer reviewed. The peer reviewer has no relevant commercial relationships to disclose.

Planners and Managers
MedEdicus planners and managers have no relevant commercial relationships to disclose.

Disclosure of Commercial Support
This continuing medical education activity is supported through an educational grant from Arena Pharmaceuticals, Inc.

Off-Label Discussion
This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.

Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at info@mededicus.com.

Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC or Arena Pharmaceuticals, Inc.

This CME/CE activity is copyrighted to MedEdicus LLC ©2021. All rights reserved. 243